Navigation Links
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, randomized study enrolled 50 subjects with SP-MS. A total of 36 subjects received PI-2301 once weekly for 8 weeks followed by an open label extension of an additional 4 weeks. The doses ranged from 1 to 60 mg. Safety at all doses, including potentially therapeutic doses, was established. The most frequent adverse events (AEs) were dose-dependent site reactions which were mild to moderate, transient, and resolved without specific therapy. Dose-dependent increases in serum levels of anti-inflammatory markers were consistent with PI-2301 exposure as measured using the Company's proprietary pharmacokinetic assay. The Company plans to continue developing this promising compound by initiating a Phase II study in multiple sclerosis patients later this year.

"PI-2301 has now shown safety and pharmacologic activity in two clinical studies, the first in healthy volunteers, and this second in patients with multiple sclerosis. As we look forward to the Phase II, we are excited about the observed pharmacologic effects of PI-2301 in patients suffering from secondary progressive MS," stated Thomas P. Mathers, President and CEO of Peptimmune.

Data from this Phase Ib study will be presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dr. Eric Zanelli will make a poster presentation titled "Clinical and biological results of a 12-week, double-blind, multiple ascending dose study evaluating the safety and tolerability of peptide copolymer PI-2301 in patients with the secondary progressive form of multiple sclerosis." The poster (P-422) will be presented within Topic 15 - Immunomodulation - 1 during the Poster Session I taking place on Thursday, September 10, 2009, between 2:30 and 5:00 p.m.

About PI-2301

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in autoimmune diseases such as multiple sclerosis. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis and other autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

In January 2009 Peptimmune granted Novartis (NYSE: NVS) an exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301.

About Multiple Sclerosis

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system attacks components of nerves. The effects of these immune-mediated attacks often progress to a chronic disabling disease, as communication between the brain and other parts of the body is disrupted.

About Peptimmune (

Peptimmune, Inc. is a privately held biotechnology company clinically focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP(TM) Technology to design peptide copolymers for the diagnosis and treatment of infectious diseases, autoimmune disorders, and the generation of novel antibodies. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.

SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peptimmune Presentations at Upcoming Events
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Peptimmune Announces First Close of Series D Private Financing
4. Cephalon Completes Acquisition of Arana Therapeutics
5. Cardinal Health Completes Biotech Acquisition
6. Beckman Coulter Completes Acquisition of Olympus Lab-Based Diagnostics Business
7. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
8. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
9. GlaxoSmithKline Completes Acquisition of Stiefel
10. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
11. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero ... of organotypic 3D cell culture models, has launched a 14 Day Hepatotoxicity ... patent-pending 3D InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity testing of ...
(Date:10/13/2015)... Research and Markets( ) has announced ... for Bone Morphogenetic Protein Growth Factor Therapy - 16 ... --> --> Bone morphogenetic proteins ... bone after a fracture. In nature, these proteins have ... of the skeleton. There are twenty different BMPs that ...
(Date:10/13/2015)... October 13, 2015 " Microbiology Culture ... 2015 - 2023 " , the global microbiology ... anticipated to reach US$7.59 bn by 2023, expanding at a CAGR ... --> " Microbiology Culture Market - Global Industry Analysis, ... , the global microbiology culture market was valued at ...
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx Inc. , a ... received a Phase I Small Business Innovative Research (SBIR) grant (1R43GM112204-01A1). This Phase ... Sciences (NIGMS), will fund the development of a technique to rapidly convert single-chain ...
Breaking Biology Technology:
(Date:10/6/2015)... Calif. , Oct. 6, 2015  Maverix ... today announced enhancements to its software portfolio with ... analysis kit for differential expression in eukaryotes. The ... which is a cloud-based genomic analysis solution that ... scientific discovery from next-generation sequencing efforts. ...
(Date:10/2/2015)... , Oct. 02 2015 ... of the "Enforcing the Law Using Biometrics" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Enforcing the Law Using Biometrics" ...
(Date:9/30/2015)...  With nearly 300,000 Americans living with spinal cord ... to reach 12,500 annually, the role of Independent Living ... Independent Living (SCRS-IL) is increasingly important. SCRS-IL is ... opening doors to independence for individuals with SCIs ... assistive technology services and education. "In serving ...
Breaking Biology News(10 mins):